Synvista Therapeutics, Inc. (AMEX: SYI), a biopharmaceutical company, is focused on the development of drugs to treat and prevent cardiovascular disease and nephropathy in people with diabetes. The Company has identified multiple product candidates innovatively approach some of the largest pharmaceutical markets. The Company’s portfolio includes orally bioavailable, organoselenium mimics of glutathione peroxidase. For further information, visit the Company’s web site at www.alteon.com.
- 18 years ago
QualityStocks
Synvista Therapeutics, Inc. (AMEX: SYI)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – Information Services Group (NASDAQ: III) Rings Nasdaq Closing Bell To Mark 20th Anniversary
Information Services Group (NASDAQ: III) will mark its 20th anniversary by ringing the closing bell on May 5, 2026, at…
-
QualityStocksNewsBreaks – MindBio Therapeutics Corp. (CSE: MBIO; Frankfurt: WF6; OTCQB: MBQIF) Develops Cross-Language AI Model For Intoxication Detection
This article has been disseminated on behalf of MindBio Therapeutics Corp. and may include paid advertising. MindBio Therapeutics (CSE: MBIO;…
-
QualityStocksNewsBreaks – Forward Industries, Inc. (NASDAQ: FWDI) Invests In OnRe And Plans $25M Deployment Into Tokenized Reinsurance Platform
Forward Industries (NASDAQ: FWDI) announced a strategic investment in onchain reinsurance company OnRe as part of its $5 million Series…